EMV 1.64% $2.02 emvision medical devices ltd

Ann: EMVision Commences Clinical Trial, page-34

  1. 13,481 Posts.
    lightbulb Created with Sketch. 2673
    We will have to be patient because progress 'hints' on the most important trial endpoints - i.e. clinical efficacy - are unlikely before mid year or later.

    Nevertheless, news flow in the first 6 months is likely to include:
    1. Progress with recruitment
    2. Commencement of trials at PA and Melbourne Hospitals (unless all 30 Phase 1 recruits are scheduled for Liverpool)
    3. Results of Phase 1 - device validation and safety confirmation (in accordance with TGA requirements) and algorithm enhancement
    4. Updated timetable for Phase 2 - specificity and sensitivity

    Great time for a top-up!
    Last edited by vintage: 18/01/23
 
watchlist Created with Sketch. Add EMV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.